| Investigator, Principal |
NCT03929731: Long-term Outcomes, Recurrence Rates, and Treatment Needs in Polypoidal Choroidal Vasculopathy (PCV) |
|
|
| Recruiting | N/A | 72 | RoW | Indocyanine Green Angiography, Optical Coherence Tomography-Angiography, Fundus photography, Fundus fluorescein, Optical Coherence Tomography | Singapore National Eye Centre | Polypoidal Choroidal Vasculopathy | 06/25 | 06/25 | | |
NCT05769751: A Study to Describe the Real-world Treatment Patterns and Associated Outcomes in Patients of China With HER2-positive Unresectable or Metastatic Breast Cancer |
|
|
| Completed | N/A | 865 | RoW | Electronic medical record and hospital information system or other available resources | Daiichi Sankyo, Inc. | HER2-positive Breast Cancer | 07/23 | 07/23 | | |
BIOPATTERN, NCT06259019: Liquid Biopsy System Intracoronary Blood Sampling and Analysis to Characterise Disease Biomarkers in Patients With Coronary Disease |
|
|
| Recruiting | N/A | 300 | Europe | Liquid Biopsy System (LBS), LBS | PlaqueTec Ltd, Royal Papworth Hospital | Coronary Artery Disease | 05/25 | 07/25 | | |
| Completed | N/A | 63 | US | Healthy Child Development Program | University of South Carolina | Child Behavior, Child Health, Child, Preschool, Parents | 01/24 | 01/24 | | |
| Active, not recruiting | N/A | 15886 | Canada, US | Limited Intraoperative Benzodiazepine, Liberal Intraoperative Benzodiazepine | Population Health Research Institute | Delirium, Post-cardiac Surgery | 07/24 | 07/24 | | |
| Active, not recruiting | N/A | 32 | RoW | | University of Sydney, Western Sydney Local Health District | Head and Neck Neoplasms, Radiation Therapy Complication | 12/24 | 12/24 | | |
EUROPA T-DXd, NCT05458401: EUropean Real-world Experience Of Previously Treated Advanced/Metastatic HER2-positive Breast Cancer Patients Accessing Trastuzumab Deruxtecan |
|
|
| Completed | N/A | 256 | Europe | Trastuzumab deruxtecan, T-DXd | Daiichi Sankyo | HER2-positive Breast Cancer | 12/23 | 12/23 | | |
OPBIM, NCT06353464: A Translational Understanding of Obesity-Related Phenotypes Using Brain Imaging and Manipulation |
|
|
| Recruiting | N/A | 80 | US | Ensure and Water | Drexel University | Obesity | 09/25 | 09/25 | | |
NCT06099639: Medical Access Program for Patritumab Deruxtecan |
|
|
| Available | N/A | | US | HER3-DXd, U3-1402 | Daiichi Sankyo | Epidermal Growth Factor Receptor (EGFR)-Mutated Non Small Cell Lung Cancer | | | | |
HHiNPWT7DC, NCT05559697: Study Comparing iNPWT Dressing and Devices Affect on Bioburden Levels and Skin Condition After Seven Days |
|
|
| Completed | N/A | 16 | US | Sponsor incisional negative pressure wound therapy device and dressing, Standard of Care incisional negative pressure wound therapy system | DeRoyal Industries, Inc., Lincoln Memorial University | Skin Reaction to Mechanical, Thermal and Radiation Stimuli, Skin Sensitisation | 03/24 | 03/24 | | |
MEE, NCT04730700: Evaluation of Multi-Tined Expandable Electrode () Efficacy and Safety in Treatment of Lumbar Facet Arthropathy by Radiofrequency Neurotomies Compared to Conservative Medical Management. |
|
|
| Recruiting | N/A | 50 | US | Radiofrequency Ablation with MEE, Conventional Medical Management | University of Kansas Medical Center | Chronic Low-back Pain | 11/23 | 11/23 | | |
NCT05120895: An Observational Study Investigating the Change in Blood Cholesterol With Mevalotin® Tablet Administration in Korean Menopausal Women Aged 50 Years or More Who Require Treatment of Dyslipidemia |
|
|
| Active, not recruiting | N/A | 3300 | RoW | Mevalotin | Daiichi Sankyo, Daiichi Sankyo Korea Co., Ltd. | Dyslipidemia | 04/25 | 04/25 | | |
NCT05606094: Real-World Observational Study to Describe Treatment Patterns in Patients With HER2-Positive Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer in East Asia |
|
|
| Completed | N/A | 450 | RoW | | Daiichi Sankyo Co., Ltd. | Gastric Cancer | 11/23 | 11/23 | | |
NCT03866707: Epigenetic and Metabolomic Changes in Childhood Cancer Survivors |
|
|
| Terminated | N/A | 7 | US | One-time blood draw, Evaluation of CpG methylation, Metabolomic analysis | Wake Forest University Health Sciences | Childhood Cancer | 05/20 | 05/20 | | |
| Completed | N/A | 11 | US | Psychosocial intervention | Medical University of South Carolina | Aphasia, Stroke | 12/23 | 12/23 | | |
NCT06210776: A Study to Assess the Effectiveness of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH) |
|
|
| Recruiting | N/A | 800 | RoW | Trastuzumab deruxtecan, T-DXd | Daiichi Sankyo | HER2-positive Breast Cancer, HER2-low Breast Cancer, Breast Cancer, Advanced Cancer | 03/28 | 03/28 | | |
NCT04910048: Impact of a POPOP on Preoperative Health, Eligibility, and Clinical & Patient-Reported Outcomes in TJA |
|
|
| Active, not recruiting | N/A | 46 | US | POPOP (preoperative patient optimization program), 20Lighter, SOC (standard of care) | University of Arkansas | Osteoarthritis, Knee, Osteoarthritis, Hip, Avascular Necrosis, Rheumatoid Arthritis | 04/23 | 12/24 | | |
NCT06204900: A Post-marketing Study to Evaluate a Novel Surgical Monitoring Technique Using the EARP Nerve Cuff in TLIF Surgery. |
|
|
| Not yet recruiting | N/A | 30 | US | Nerve Cuff and Retractor System | Retropsoas Technologies, LLC | Undergoing a Single-level or Two-level TLIF Surgery | 06/24 | 08/24 | | |
ACAB, NCT04292405: Accuracy of Cardiac Acoustic Biomarkers Recorded by the Wearable Cardioverter Defibrillator |
|
|
| Recruiting | N/A | 60 | US | Wearable Cardioverter Defibrillator, AUDICOR AM | Zoll Medical Corporation | Heart Failure | 03/24 | 05/24 | | |
| Recruiting | N/A | 60 | US | BHmApp | William Beaumont Hospitals, University of Pennsylvania | Urinary Incontinence | 08/24 | 08/24 | | |
| Recruiting | N/A | 200 | Europe | | Chelsea and Westminster NHS Foundation Trust, ViiV Healthcare | HIV Infections, Gender Identity, Human Immunodeficiency Virus | 04/24 | 10/25 | | |
| Active, not recruiting | N/A | 70 | US | PQ Bypass System | Endologix | Peripheral Artery Diseases | 06/24 | 06/24 | | |
NCT03586414: MitoQ Supplementation and Cardiovascular Function in Healthy Men and Women |
|
|
| Active, not recruiting | N/A | 31 | US | MITOQUINOL MESYLATE then placebo, MitoQ, Mitoquinol methanesulfonate, Placebo, then MITOQUINOL MESYLATE | University of Colorado, Denver, University of Colorado Nutrition Obesity Research Center (NORC) | Diastolic Dysfunction | 07/25 | 08/25 | | |
NCT06361797: Varying Bone Marrow-Derived Mesenchymal Stem Cells Concentrations' Impact on Rotator Cuff Repair Outcomes |
|
|
| Not yet recruiting | N/A | 150 | US | Rotator cuff repair augmented with whole bone marrow, Whole bone marrow, Bone marrow aspirate, Rotator cuff repair augmented with concentrated bone marrow, Bone marrow-derived mesenchymal stem cells, Bone marrow concentrate | Johns Hopkins University, ON Foundation | Rotator Cuff Tears | 07/26 | 12/27 | | |
NCT06340503: Evaluating a Physical Activity Index for Assessment and Counseling for Breast and Colon Cancer Survivors |
|
|
| Recruiting | N/A | 20 | US | Research-grade accelerometer, National Comprehensive Cancer Network (NCCN) Education Materials, Garmin Vivofit activity tracker, Exercise Consultation Calls, Interview, Physical Activity Index Assessment (Intervention Arm), Physical Activity Index Assessment (Control Arm), Health Surveys | Wake Forest University Health Sciences, National Cancer Institute (NCI) | Breast Cancer, Colon Cancer | 07/25 | 08/25 | | |
NCT02945085: 3D Team Care for Cognitively Vulnerable Older Adults |
|
|
| Recruiting | N/A | 576 | US | Home Based Care Team, Telephone Based Care Team | UConn Health, Patient-Centered Outcomes Research Institute, University of Connecticut | Dementia, Depression, Delirium | 07/24 | 07/24 | | |
NCT04931251: Addressing Cancer-Related Financial Toxicity in Rural Oncology Care Settings |
|
|
| Recruiting | N/A | 780 | US | Financial Navigation | UNC Lineberger Comprehensive Cancer Center, National Cancer Institute (NCI) | Neoplasms, Carcinoma | 07/24 | 07/24 | | |
| Active, not recruiting | N/A | 80 | US | Gaming in a virtual environment | Yale University, National Heart, Lung, and Blood Institute (NHLBI) | Cardiovascular Diseases | 07/25 | 07/25 | | |
NCT04927052: A Study to Evaluate the Safety and Efficacy of Revanesse Shape + With Lidocaine Versus Juvederm Voluma With Lidocaine for the Correction of Age-Related Midface Volume Deficit / Lipoatrophy at 6 and 12 Months Post-treatment |
|
|
| Completed | N/A | 136 | Canada | Revanesse Shape + with Lidocaine, Juvederm Voluma with Lidocaine. | Prollenium Medical Technologies Inc. | Volume Deficit in the Mid-face | 08/23 | 08/23 | | |
| Not yet recruiting | N/A | 16 | US | KeraStat cream, M-PART Assessments via MyCap, Clinical Assessments, Feedback phone interview | Wake Forest University Health Sciences, National Cancer Institute (NCI) | Radiation Dermatitis | 08/26 | 08/26 | | |
| Active, not recruiting | N/A | 5000 | RoW | Edoxaban | Daiichi Sankyo, Inc., Daiichi Sankyo (China) Holdings Co., Ltd. | Non-valvular Atrial Fibrillation | 10/24 | 10/24 | | |
ROCK-RT, NCT05169177: Radio-opaque Contrast Agents for Liver Cancer Targeting With KIM During Radiation Therapy |
|
|
| Recruiting | N/A | 50 | RoW | | University of Sydney, Calvary Mater Newcastle, Australia, Western Sydney Local Health District, Austin Health, Peter MacCallum Cancer Centre, Australia, Princess Alexandra Hospital, Brisbane, Australia | Liver Neoplasm | 10/24 | 10/26 | | |
NCT01336790: International Lymphatic Disease and Lymphedema Registry |
|
|
| Recruiting | N/A | 5000 | US | | Stanford University, Lymphatic Education & Research Network | Lymphedema | 12/24 | 12/25 | | |
NCT05531357: Physiologic Mechanisms Underlying Ovarian Follicular Waves During the Menstrual Cycle |
|
|
| Completed | N/A | 50 | Canada | Transvaginal ultrasound scans, Finger-prick blood sampling for dried blood spots, Urine sampling, Venipunctures | University of Saskatchewan, Ansh Labs | Reproductive Issues | 03/24 | 03/24 | | |
| Recruiting | N/A | 200 | US | Education and counseling, Education | Georgetown University | Breast Cancer | 12/24 | 12/25 | | |
NCT05689190: Non-invasive Flow Measurements in Patients With Lower Extremity Arterial Disease (LEAD) |
|
|
| Recruiting | N/A | 30 | Europe | | Philips Clinical & Medical Affairs Global, Leiden University Medical Center | Lower Extremity Arterial Disease | 12/24 | 12/24 | | |
NCT05862467: A Pilot Participatory Program Evaluation of a Virtual Trauma Support Program for Autistic Adults |
|
|
| Recruiting | N/A | 30 | US | Written Exposure Therapy (WET) via telehealth | University of Wyoming | Autism, Trauma, Posttraumatic Stress Disorder, Posttraumatic Stress Symptom | 05/25 | 05/25 | | |
NCT04635111: A Long-term Study Evaluating Hepatotoxicity Associated With TURALIO™ (Pexidartinib) Treatment |
|
|
| Recruiting | N/A | 30 | US | TURALIO™ | Daiichi Sankyo, Inc. | Hepatotoxicity, Tenosynovial Giant Cell Tumor | 06/25 | 03/36 | | |
| Recruiting | N/A | 198 | US | Dietary Intervention Classes | University of South Carolina | Diabetes Mellitus, Type 2, Obesity | 12/25 | 03/26 | | |
MILOS, NCT04579367: Treatment With Bempedoic Acid and/or Its Fixed-dose Combination With Ezetimibe in Primary Hypercholesterolemia or Mixed Dyslipidemia |
|
|
| Recruiting | N/A | 5000 | Europe | Bempedoic acid and/or its fixed-dose combination with ezetimibe | Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company | Hypercholesterolemia, Mixed Dyslipidemia | 09/25 | 09/25 | | |
NCT06054412: An Adjunctive Neurofeedback Training Program to Enhance Wellness Among Trauma-Exposed Postpartum Mothers |
|
|
| Recruiting | N/A | 20 | US | Neuroptimal (Zengar, Inc.) Neurofeedback | Wayne State University | Well-Being, Psychological, Dissociation, Maternal Care Patterns, Maternal Behavior, Maternal Distress, Mood Disturbance, Emotional Regulation, Post Traumatic Stress Disorder | 09/25 | 03/26 | | |
| Active, not recruiting | N/A | 7 | US | Actual device PFO closure, GORE® CARDIOFORM Septal Occluder, Thienopyridine (clopidogrel or prasugrel), Plavix, Effient, Sham device PFO closure | W.L.Gore & Associates | Migraine, Patent Foramen Ovale, PFO - Patent Foramen Ovale | 12/25 | 08/26 | | |
SILVERCARE_AF, NCT05804747: A Study to Evaluate Effectiveness and Safety of Edoxaban in Patients 80 Years of Age or Older With Nonvalvular Atrial Fibrillation |
|
|
| Recruiting | N/A | 1100 | RoW | Edoxaban | Daiichi Sankyo, Daiichi Sankyo Korea Co., Ltd. | Atrial Fibrillation | 12/25 | 12/25 | | |
LEARN, NCT05184790: Learning Environment for Artificial Intelligence in Radiotherapy New Technology |
|
|
| Not yet recruiting | N/A | 300 | RoW | | University of Sydney, Princess Alexandra Hospital, Brisbane, Australia, Calvary Mater Newcastle, Australia, Western Sydney Local Health District, Austin Health, Peter MacCallum Cancer Centre, Australia | Arrhythmias, Cardiac, Breast Cancer, Prostatic Cancer, Brain Cancer, Kidney Cancer, Head and Neck Cancer, Liver Cancer, Pancreatic Cancer, Spinal Neoplasm | 01/26 | 01/26 | | |
NCT05022862: Economic Incentives and vDOT for Latent Tuberculosis Infection |
|
|
| Recruiting | N/A | 399 | US | Usual Care, Video Directly Observed Therapy alone, Video Directly Observed Therapy plus Financial Incentives | Johns Hopkins University, National Institute of Allergy and Infectious Diseases (NIAID) | Latent Tuberculosis | 04/26 | 10/26 | | |
NCT05993234: A Study of Trastuzumab DeRuxtecan for Patients With Advanced HER2-pOsitive GaStric or GastroesoPhageal Junction AdEnocarcinoma Who Have Received a PrIor Trastuzumab-based Regimen Accompanied by a Disease RegistrY of Patients Treated With Conventional Therapies (PROSPERITY) |
|
|
| Recruiting | N/A | 257 | Europe | Trastuzumab deruxtecan, T-DXd, ENHERTU® | Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company | HER2-positive Advanced Gastric Cancer, HER2-positive Gastroesophageal Junction Adenocarcinoma | 12/26 | 09/27 | | |
| Recruiting | N/A | 1350 | Europe | Trastuzumab deruxtecan, T-DXd | Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company | Unresectable Breast Cancer, Metastatic Breast Cancer, HER2-low Expressing Breast Cancer | 06/27 | 09/28 | | |
NCT05636397: Safety and PK-PD Study of Oral L-CIT in Preterm Infants With BPD±PH and NEC |
|
|
| Recruiting | N/A | 60 | Canada | L-Citrulline | The Hospital for Sick Children | BPD - Bronchopulmonary Dysplasia, Pulmonary Hypertension, NEC | 12/27 | 03/28 | | |
NCT05181163: Biofilm Formation and Antibiotic Sensitivity Patterns |
|
|
| Not yet recruiting | N/A | 100 | NA | swab | Sohag University | Orthopedic Surgery | 07/22 | 01/23 | | |
| Fitzal, Florian |
| Completed | N/A | 90 | Europe | Surgery, Surgery on Demand | Austrian Breast & Colorectal Cancer Study Group, Bayer, Amgen, Hoffmann-La Roche, AstraZeneca, Sanofi Aventis GmbH, Austria, Wyeth Lederle Pharma GmbH, Austria, GlaxoSmithKline, Merck Sharp & Dohme LLC, Fond of the Viennese Mayor | Synchronous Metastasized Breast Cancer, Circulating Tumor Cells | 07/22 | 07/22 | | |
OPBC-02PREPEC, NCT04293146: Pre- Versus Sub-pectoral Implant-based Breast Reconstruction After Skin-sparing Mastectomy or Nipple-sparing Mastectomy |
|
|
| Active, not recruiting | N/A | 382 | Europe, US | pre-pectoral IBBR, sub-pectoral IBBR | University Hospital, Basel, Switzerland, Swiss National Science Foundation | Breast Reconstruction, Implant-Based Breast Reconstruction (IBBR) | 02/32 | 02/33 | | |
| Singer, Christian |
EMBER-3, NCT04975308 / 2021-000079-35: A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer |
|
|
| Recruiting | 3 | 860 | Europe, Japan, US, RoW | Imlunestrant, LY3484356, Exemestane, Fulvestrant, Abemaciclib, LY2835219 | Eli Lilly and Company, Eli Lilly and Company | Breast Neoplasms, Neoplasm Metastasis | 04/24 | 08/27 | | |
| Recruiting | 3 | 650 | Europe, Canada, Japan, US, RoW | Tucatinib, TUKYSA, ONT-380, ARRY-380, Trastuzumab, Herceptin, Herceptin Hylecta, Pertuzumab, Perjeta, Combination product: Trastuzumab + Pertuzumab, Phesgo, Placebo | Seagen Inc., Merck Sharp & Dohme LLC | HER2 Positive Breast Cancer | 10/24 | 06/27 | | |
ZEST, NCT04915755 / 2020-003973-23: Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease |
|
|
| Active, not recruiting | 3 | 40 | Europe, Canada, Japan, US, RoW | Niraparib, Placebo | GlaxoSmithKline | Neoplasms, Breast | 03/25 | 08/29 | | |
|
TAXIS, NCT03513614: Tailored Axillary Surgery With or Without Axillary Lymph Node Dissection Followed by Radiotherapy in Patients With Clinically Node-positive Breast Cancer |
|
|
| Recruiting | 3 | 1500 | Europe, RoW | Tailored axillary surgery - both Arms, Radiotherapy - Arm A, Radiotherapy - Arm B | University Hospital, Basel, Switzerland, ETOP IBCSG Partners Foundation, Austrian Breast Cancer Study Group | Node-positive Breast Cancer | 12/29 | 12/36 | | |
NCT03301493: Genomic Testing and Resulting Medical Decisions |
|
|
| Recruiting | N/A | 1000 | Europe | Genomic testing | Arbeitsgemeinschaft medikamentoese Tumortherapie, Roche Pharma AG, AstraZeneca | Cancer of Unknown Origin, Cancer Refractory, Cancer of Stomach, Cancer Head Neck, Cancer of Skin, Cancer, Lung, Cancer Colorectal, Cancer of Esophagus, Cancer, Bladder, Cancer, Uterus, Cancer Cervix, Cancer Liver, Cancer, Kidney, Cancer, Breast, Hematologic Neoplasms | 12/24 | 12/24 | | |
| Recruiting | N/A | 3000 | Europe | | Arbeitsgemeinschaft medikamentoese Tumortherapie, Hoffmann-La Roche, Daiichi Sankyo, Pfizer, Novartis, Caris Life Science, AstraZeneca, Seagen Inc., Eli Lilly and Company | Breast Cancer, Breast Carcinoma, Breast Tumor | 06/25 | 06/25 | | |
| Jilma, Bernd |
| Suspended | 3 | 57 | Europe, Canada, Japan, US, RoW | Pegcetacoplan, Aspaveli | Swedish Orphan Biovitrum, Swedish Orphan Biovitrum AB | Cold Agglutinin Disease | 10/24 | 10/24 | | |
| Recruiting | 2/3 | 500 | Europe | Chloroquine or Hydroxychloroquine, Lopinavir/Ritonavir, Best standard of care, Rivaroxaban, Thromboprophylaxis, Candesartan, non-RAS blocking antihypertensives, Remdesivir, Asunercept 400mg, Asunercept 100mg, Asunercept 25mg, Pentaglobin | Medical University of Vienna, Kaiser Franz Josef Hospital, SMZ-Ost Donauspital, Otto Wagner Hospital, Hospital Hietzing, Wilhelminenspital Vienna, Medical University Innsbruck, Medical University of Graz, Kepler University Hospital | COVID-19 | 12/21 | 03/22 | | |
| Completed | 2 | 22 | Europe | Felzartamab, MOR202, CD38 monoclonal antibody, Placebo, 0.9% Saline | Farsad Eskandary, Charite University, Berlin, Germany, University of Alberta, HI-Bio | Antibody-mediated Rejection | 03/24 | 03/24 | | |
NCT04941183: Phase 1 Study to Assess Safety, Tolerability, PD, PK, Immunogenicity of IV NTR-441 Solution in Healthy Volunteers and COVID-19 Patients |
|
|
| Terminated | 1 | 52 | Europe, RoW | NTR-441, Placebo | Neutrolis | Covid19 | 12/22 | 06/23 | | |
| Polterauer, Stephan |
| Active, not recruiting | 3 | 568 | Europe, Canada, Japan, US, RoW | tisotumab vedotin, TIVDAK, topotecan, vinorelbine, gemcitabine, irinotecan, pemetrexed | Seagen Inc., Genmab | Cervical Cancer | 07/23 | 08/25 | | |
| Recruiting | 3 | 540 | Europe | Letrozole 2.5mg, Femara, Placebo | Swiss GO Trial Group, AGO Study Group, Arbeitsgemeinschaft Gynaekologische Onkologie Austria, Reliable Cancer Therapies, Krebsliga Schweiz, Stiftung Guido Feger, Hoffmann-La Roche, Helsana AG, Novartis Pharmaceuticals, Anticancer Fund, Belgium | Ovarian Neoplasm Epithelial, Fallopian Tube Neoplasms, Peritoneal Neoplasms, High-grade Serous Ovarian Carcinoma (HGSOC), Low-grade Serous Ovarian Carcinoma (LGSOC), Ovarian Endometrioid Carcinoma | 10/25 | 10/30 | | |
NCT05797831: Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer |
|
|
| Recruiting | 2/3 | 268 | Europe, Canada, US, RoW | Navtemadlin, KRT-232, Navtemadlin Placebo | Kartos Therapeutics, Inc., European Network of Gynaecological Oncological Trial Groups (ENGOT), GOG Foundation | Endometrial Cancer | 08/25 | 07/27 | | |
| Reinthaller, Alexander |
| Recruiting | 3 | 540 | Europe | Letrozole 2.5mg, Femara, Placebo | Swiss GO Trial Group, AGO Study Group, Arbeitsgemeinschaft Gynaekologische Onkologie Austria, Reliable Cancer Therapies, Krebsliga Schweiz, Stiftung Guido Feger, Hoffmann-La Roche, Helsana AG, Novartis Pharmaceuticals, Anticancer Fund, Belgium | Ovarian Neoplasm Epithelial, Fallopian Tube Neoplasms, Peritoneal Neoplasms, High-grade Serous Ovarian Carcinoma (HGSOC), Low-grade Serous Ovarian Carcinoma (LGSOC), Ovarian Endometrioid Carcinoma | 10/25 | 10/30 | | |
NCT04369352: Register to Describe the Treatment Pattern of Platinum-sensitive Relapsed Epithelial Ovarian Cancer Patients in Austria |
|
|
| Recruiting | N/A | 150 | Europe | | Medical University Innsbruck | Recurrent Ovarian Carcinoma | 12/24 | 08/25 | | |
NCT01789229: Establishment of a Tumor Bank for Tissue Samples |
|
|
| Recruiting | N/A | 10000 | Europe | Tumor tissue collection, Sampling of ascites and pleural effusion, Collecting urine samples, Collecting saliva sample, Collecting sputum, Collecting stool samples, Lavage/Irrigation | Medical University of Vienna | Ovarian Neoplasms, Breast Neoplasms, Colorectal Neoplasms, Neoplasms of the Female Genitalia, Lung Neoplasms, Endocrine Gland Neoplasms | 12/26 | 12/26 | | |
| Ullrich, Roman |
NCT02121275: Lung Ultrasound for the Detection of Pulmonary Atelectasis in the Perioperative Period |
|
|
| Active, not recruiting | N/A | 25 | Europe | Ultrasound of the lungs, Sonosite ultrasound device (M-Turbo), Electric impedance tomography, EIT (Pulmovista, Draeger) | Medical University of Vienna | Postoperative Pulmonary Atelectases | 06/16 | 06/23 | | |
NCT05222542: Angiotensin Metabolite Profile After Subarachnoid Hemorrhage |
|
|
| Recruiting | N/A | 60 | Europe | Sampling of plasma and cerebrospinal fluid at specified time points | Dr. Roman Ullrich, Austrian Science Fund (FWF) | Subarachnoid Hemorrhage, Aneurysmal | 02/25 | 02/25 | | |
| Bartsch, Rupert |
| Recruiting | 3 | 400 | Europe | Palbociclib 125mg, Ibrance, PD-0332991, Standard endocrine therapy | ETOP IBCSG Partners Foundation, Pfizer | Breast Cancer Recurrent | 07/24 | 11/26 | | |
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer |
|
|
| Recruiting | 3 | 6000 | Europe, Canada, Japan, US, RoW | Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane | Eli Lilly and Company | Breast Neoplasms | 10/27 | 03/32 | | |
| Completed | 2 | 15 | Europe | Trastuzumab deruxtecan, Ds8201a, Enhertu | Medical University of Vienna, Daiichi Sankyo, Inc. | Breast Cancer Stage IV | 05/23 | 05/23 | | |
|
TUXEDO-3, NCT05865990: HER3-DXd in Breast Cancer and NSCLC Brain Metastases and Solid Tumor Leptomeningeal Disease |
|
|
| Recruiting | 2 | 60 | Europe | Patritumab deruxtecan, HER3-DXd | MedSIR, Daiichi Sankyo | Metastatic Breast Cancer, Advanced Non-Small Cell Squamous Lung Cancer, Solid Tumor, Adult | 12/25 | 10/26 | | |
TUXEDO-2, NCT05866432: Phase II Study of Dato-DXd in Triple-negative Breast Cancer Patients With Newly Diagnosed or Progressing Brain Metastases |
|
|
| Recruiting | 2 | 20 | Europe | Datopotamab deruxtecan, S-1062a | Medical University of Vienna, Daiichi Sankyo, Inc. | Breast Cancer Stage IV | 05/26 | 05/26 | | |
TRACE, NCT05253911: Tucatinib in Patients With Locally Advanced or Metastatic HER2-positive Breast Cancer Who Received at Least Two Prior Anti-HER2 Treatment Regimens. |
|
|
| Recruiting | N/A | 300 | Europe | TUKYSA® | iOMEDICO AG, Seagen Inc. | HER2-positive Breast Cancer | 05/27 | 05/27 | | |
| Agis, Hermine |
AFFIRM-AL, NCT04973137: A Study to Evaluate the Efficacy and Safety of Birtamimab in Mayo Stage IV Patients With AL Amyloidosis |
|
|
| Recruiting | 3 | 220 | Europe, Canada, Japan, US, RoW | Birtamimab, Placebo, Standard of Care Chemotherapy | Prothena Biosciences Ltd. | Light Chain (AL) Amyloidosis | 06/25 | 06/27 | | |
| Staber, Philipp B |
BRUIN CLL-321, NCT04666038: Study of LOXO-305 Versus Investigator's Choice (IdelaR or BR) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) |
|
|
| Active, not recruiting | 3 | 250 | Europe, Canada, Japan, US, RoW | LOXO-305, Pirtobrutinib, Idelalisib, Zydelig, Bendamustine, Treanda, Treakisym, Ribomustin, Levact, Rituximab, Rituxan, MabThera, Truxima | Loxo Oncology, Inc., Eli Lilly and Company | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 11/23 | 05/27 | | |
CLL17, NCT04608318 / 2019-003854-99: Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients With Previously Untreated Chronic Lymphocytic Leukaemia (CLL) |
|
|
| Active, not recruiting | 3 | 897 | Europe, RoW | Ibrutinib, Imbruvica, Venetoclax, ABT-199, Venclyxto, Obinutuzumab, GA101, Gazyvaro | German CLL Study Group, Stichting Hemato-Oncologie voor Volwassenen Nederland (HOVON), Nordic CLL Study Group (NCLLSG), Swiss Group for Clinical Cancer Research (SAKK), Cancer Trials Ireland, Gruppo Italiano Malattie EMatologiche dell'Adulto (GIMEMA), Grupo Español de Leucemia Linfocítica Crónica (GELLC), The Israeli CLL Study Group (ICLLSG) | Chronic Lymphoid Leukemia | 03/27 | 03/27 | | |
NCT04263480: Efficacy and Safety of Carfilzomib in Combination With Ibrutinib vs Ibrutinib in Waldenström's Macroglobulinemia |
|
|
| Recruiting | 2 | 99 | Europe | Carfilzomib + Ibrutinib, Ibrutinib | Christian Buske, Amgen, Janssen, LP | Waldenstrom Macroglobulinemia | 02/28 | 02/28 | | |
EXALT-2, NCT04470947: Comprehensive Genomic Profiling and Next Generation Functional Drug Screening for Patients With Aggressive Haematological Malignancies |
|
|
| Recruiting | N/A | 150 | Europe | Next generation functional drug screening, Comprehensive genomic profiling, FoundationOne Heme | Medical University of Vienna, Roche Pharma AG, Allcyte GmbH | Advanced Lymphoma, Refractory Lymphoma, Refractory Leukemia, Refractory Acute Myeloid Leukemia, Refractory T-Cell Lymphoma | 03/26 | 03/26 | | |
| Restrepo, Alvaro |
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer |
|
|
| Recruiting | 3 | 6000 | Europe, Canada, Japan, US, RoW | Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane | Eli Lilly and Company | Breast Neoplasms | 10/27 | 03/32 | | |
| Active, not recruiting | N/A | 3000 | US | Breast Cancer Index (BCI) Risk of Recurrence & Extended Endocrine Benefit Test, Breast Cancer Index (BCI) Test | Biotheranostics, Inc. | Breast Cancer | 12/28 | 12/28 | | |
| Schlager, Oliver |
ARIVA, NCT04128956: Aspirin® Plus Rivaroxaban Versus Rivaroxaban Alone for the Prevention of Venous Stent Thrombosis in Patients With PTS |
|
|
| Terminated | 2 | 172 | Europe | Aspirin 100mg, Aspirin | University of Zurich, University Hospital Heidelberg, Medical University of Vienna, RWTH Aachen University, Klinikum Arnsberg, University Hospital Freiburg | Venous Thromboses, Stent Stenosis | 02/24 | 02/24 | | |
LIMES, NCT04772300: Trial to Assess the Safety and Efficacy of Sirolimus-Coated Balloon vs. Uncoated Standard Angioplasty for the Treatment of Below-the-knee Peripheral Arterial Disease |
|
|
| Recruiting | N/A | 230 | Europe | Percutaneous Transluminal Angioplasty (PTA) MagicTouch Sirolimus Coated PTA Balloon Catheter, Percutaneous Transluminal Angioplasty (PTA) with non-coated balloon catheter (POBA) | Jena University Hospital, Concept Medical Inc., Vascuscience, CoreLab Black Forest, Center for Clinical Studies, University Hospital Jena | Peripheral Artery Disease | 12/27 | 09/28 | | |
| Zebenholzer, Karin |
NCT05281770: Monoclonal CGRP Antibodies for Migraine Prevention - a Nationwide Real Life Study |
|
|
| Recruiting | N/A | 1500 | Europe | Erenumab, Fremanezumab, Galcanezumab | Austrian Migraine Registry Collaboration, Medical University of Vienna, Medical University Innsbruck, Austrian Headache Society | Migraine, Migraine With Aura, Migraine Without Aura, Chronic Migraine, Episodic Migraine | 09/25 | 12/25 | | |
| Machold, Klaus |
NCT04781543 / 2020-005764-62: A Multicenter Trial to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of HZN-825 in Patients With Diffuse Cutaneous Systemic Sclerosis |
|
|
| Recruiting | 2 | 300 | Europe, Japan, US, RoW | HZN-825 BID, Placebo, HZN-825 QD | Amgen | Diffuse Cutaneous Systemic Sclerosis, Sclerosis, Systemic | 10/24 | 09/25 | | |
|
| Emminger, Wolfgang |
NCT04088396 / 2017-004495-60: A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With Systemic Juvenile Idiopathic Arthritis (sJIA) |
|
|
| Recruiting | 3 | 58 | Europe, Japan, RoW | Baricitinib, LY3009104, Tocilizumab | Eli Lilly and Company | Systemic Juvenile Idiopathic Arthritis | 10/25 | 10/25 | | |
| Recruiting | 3 | 190 | Europe, Japan, RoW | Baricitinib, LY3009104 | Eli Lilly and Company | Juvenile Idiopathic Arthritis | 12/30 | 12/30 | | |
| Greisenegger, Stefan |
TEMPO-2, NCT02398656: A Randomized Controlled Trial of TNK-tPA Versus Standard of Care for Minor Ischemic Stroke With Proven Occlusion |
|
|
| Active, not recruiting | 3 | 1274 | Europe, Canada, RoW | Tenecteplase, TNK-tPA, Antiplatelet treatment, ASA, Clopidogrel | University of Calgary | Stroke, Acute | 01/24 | 04/24 | | |
ELAN, NCT03148457: Early Versus Late Initiation of Direct Oral Anticoagulants in Post-ischaemic Stroke Patients With Atrial fibrillatioN (): an International, Multicentre, Randomised-controlled, Two-arm, Assessor-blinded Trial |
|
|
| Completed | N/A | 2013 | Europe, Japan, RoW | Early treatment with Rivaroxaban (Xarelto®), Dabigatran (Pradaxa®), Apixaban (Eliquis®) or Edoxaban (Lixiana®), Late treatment with Rivaroxaban (Xarelto®), Dabigatran (Pradaxa®), Apixaban (Eliquis®) or Edoxaban (Lixiana®) | Insel Gruppe AG, University Hospital Bern | Ischaemic Stroke | 12/22 | 05/23 | | |
| Pham, Chi M |
EMBER-3, NCT04975308 / 2021-000079-35: A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer |
|
|
| Recruiting | 3 | 860 | Europe, Japan, US, RoW | Imlunestrant, LY3484356, Exemestane, Fulvestrant, Abemaciclib, LY2835219 | Eli Lilly and Company, Eli Lilly and Company | Breast Neoplasms, Neoplasm Metastasis | 04/24 | 08/27 | | |
ZEST, NCT04915755 / 2020-003973-23: Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease |
|
|
| Active, not recruiting | 3 | 40 | Europe, Canada, Japan, US, RoW | Niraparib, Placebo | GlaxoSmithKline | Neoplasms, Breast | 03/25 | 08/29 | | |
|
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer |
|
|
| Recruiting | 3 | 6000 | Europe, Canada, Japan, US, RoW | Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane | Eli Lilly and Company | Breast Neoplasms | 10/27 | 03/32 | | |
| Stumpf-Fekete, Barbara |
ARIVA, NCT04128956: Aspirin® Plus Rivaroxaban Versus Rivaroxaban Alone for the Prevention of Venous Stent Thrombosis in Patients With PTS |
|
|
| Terminated | 2 | 172 | Europe | Aspirin 100mg, Aspirin | University of Zurich, University Hospital Heidelberg, Medical University of Vienna, RWTH Aachen University, Klinikum Arnsberg, University Hospital Freiburg | Venous Thromboses, Stent Stenosis | 02/24 | 02/24 | | |
| Woeber, Christian |
NCT05281770: Monoclonal CGRP Antibodies for Migraine Prevention - a Nationwide Real Life Study |
|
|
| Recruiting | N/A | 1500 | Europe | Erenumab, Fremanezumab, Galcanezumab | Austrian Migraine Registry Collaboration, Medical University of Vienna, Medical University Innsbruck, Austrian Headache Society | Migraine, Migraine With Aura, Migraine Without Aura, Chronic Migraine, Episodic Migraine | 09/25 | 12/25 | | |
| Karin, Zebenholzer U |
NCT05281770: Monoclonal CGRP Antibodies for Migraine Prevention - a Nationwide Real Life Study |
|
|
| Recruiting | N/A | 1500 | Europe | Erenumab, Fremanezumab, Galcanezumab | Austrian Migraine Registry Collaboration, Medical University of Vienna, Medical University Innsbruck, Austrian Headache Society | Migraine, Migraine With Aura, Migraine Without Aura, Chronic Migraine, Episodic Migraine | 09/25 | 12/25 | | |
| Kiesewetter, Barbara |
REPOSE, NCT06315010: REPotrectinib in ROS1-positive Non-small Cell Lung Cancer Patients With Active Brain mEtastasis |
|
|
| Not yet recruiting | 2 | 20 | NA | Repotrectinib, BMS-986472, TPX-0005 | MedSIR, Medical University of Vienna | NSCLC, Brain Metastases, ROS1 Gene Rearrangement | 03/27 | 04/28 | | |
| Recruiting | 2 | 40 | Europe | Cabozantinib | Karsten Gavenis | Neuroendocrine Tumors, Neuroendocrine Carcinoma | 09/24 | 10/24 | | |
NCT05868395: Efficacy of Polatuzumab, Bendamustine and Rituximab in Patients With Relapsed/ Refractory Mantle Cell Lymphoma |
|
|
| Recruiting | 2 | 16 | Europe | Polatuzumab, bendamustin und rituximab, Polivy, Bendamustin, Mabthera | Medical University of Vienna | Mantle-cell Lymphoma | 05/27 | 05/27 | | |
| Strobl, Christiane |
| Recruiting | 4 | 192 | Europe | Empagliflozin 10mg oral tablet / Semaglutide 1mg pen injector, Jardiance(R), Ozempic(R), Empagliflozin 10mg oral tablet and placebo pen injector matching semaglutide, Jardiance(R), Placebo matching empagliflozin and placebo pen injector matching semaglutide, Control / Placebo | The Deutsche Diabetes Forschungsgesellschaft e.V., Boehringer Ingelheim, German Center for Diabetes Research, Federal Ministry of Health, Germany, Ministry of Innovation, Science and Research in North Rhine-Westphalia, Novo Nordisk A/S | Type 2 Diabetes, Non-alcoholic Steatohepatitis (NASH), Non-alcoholic Fatty Liver Disease (NAFLD) | 01/25 | 12/25 | | |
